Key Points
Analysts expect $1.89 EPS and $6.91B revenue on May 7.
Gilead beat EPS estimates in two of last three quarters.
B+ Meyka grade reflects solid fundamentals and analyst consensus.
HIV, hepatitis C, and oncology segments drive quarterly performance.
Gilead Sciences, Inc. (GILD) will report first-quarter earnings on May 7, 2026, after market close. Analysts project earnings per share of $1.89 and revenue of $6.91 billion. The biopharmaceutical giant has demonstrated consistent earnings strength, beating EPS estimates in recent quarters. Investors will focus on HIV treatment sales, hepatitis C revenue trends, and oncology portfolio performance. The stock trades at $133.48 with a market cap of $165.68 billion. Meyka AI rates GILD with a grade of B+, reflecting solid fundamentals and sector positioning.
Earnings Estimates and Historical Performance
Gilead Sciences earnings preview shows analysts expecting $1.89 EPS and $6.91 billion in revenue for the upcoming quarter. This represents a critical test of the company’s growth trajectory.
Current Quarter Expectations
The $1.89 EPS estimate marks a slight decline from the previous quarter’s $1.86 actual result. However, revenue guidance of $6.91 billion sits below the prior quarter’s $7.925 billion. This sequential decline reflects typical seasonal patterns in pharmaceutical sales. The company faces pressure from generic competition in legacy products but benefits from newer drug launches.
Historical Beat Pattern
Gilead has beaten EPS expectations in two of the last three quarters. In February 2026, the company delivered $1.86 EPS against a $1.81 estimate, beating by $0.05. The August 2025 quarter showed $2.01 actual versus $1.96 expected, another beat. This consistent outperformance suggests management’s ability to control costs and drive operational efficiency. Based on this pattern, investors should watch for another potential beat.
Revenue Trend Analysis
Revenue performance shows mixed results. The February quarter delivered $7.925 billion against $7.69 billion estimated, beating by $235 million. August 2025 revenue came in at $7.081 billion versus $6.98 billion expected. The current $6.91 billion estimate represents a sequential decline but remains solid for the quarter. Investors should monitor whether core franchises maintain momentum.
Key Metrics and What to Watch
Gilead Sciences earnings preview requires understanding critical business drivers and financial health indicators. The company’s valuation and operational metrics provide important context.
Valuation and Profitability Metrics
GILD trades at a PE ratio of 16.38, below its historical average, suggesting reasonable valuation. The company maintains a strong net profit margin of 28.9%, demonstrating pricing power and operational leverage. Return on equity stands at 41%, indicating efficient capital deployment. Free cash flow per share of $7.61 supports the current dividend of $3.19 annually. These metrics suggest the company generates substantial cash despite competitive pressures.
Analyst Consensus and Rating
Thirty-two analysts rate GILD as a buy, with only three holds and no sells. This overwhelming consensus reflects confidence in the company’s pipeline and market position. Meyka AI rates GILD with a grade of B+. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The rating suggests GILD offers balanced risk-reward for investors seeking healthcare exposure.
Cash Flow and Balance Sheet Strength
Operating cash flow per share reached $8.07, while the company maintains $8.54 in cash per share. The debt-to-equity ratio of 1.09 remains manageable for a pharmaceutical company. Interest coverage of 10.7 times demonstrates strong ability to service debt. These metrics indicate financial stability to fund R&D and shareholder returns.
Business Drivers and Segment Performance
Gilead Sciences earnings will reflect performance across multiple therapeutic areas. Understanding segment dynamics helps predict quarterly results and future growth.
HIV Treatment Portfolio
The HIV franchise remains Gilead’s largest revenue driver. Biktarvy, Genvoya, and Descovy generate substantial recurring revenue. These products face generic competition but maintain market share through superior tolerability and efficacy profiles. Investors should monitor whether HIV revenue stabilizes or continues gradual decline. Patent cliffs on legacy products create headwinds, but newer formulations provide growth opportunities.
Hepatitis C and Liver Disease Revenue
Hepatitis C treatments like Epclusa and Harvoni generate declining revenue as the treatable patient population shrinks. This segment faces structural headwinds from cure rates and generic competition. However, Vemlidy for chronic hepatitis B offers growth potential. Investors should watch for stabilization signals in this segment.
Oncology and Cell Therapy Growth
Yescarta and Tecartus represent high-margin cell therapy products with significant growth potential. Trodelvy shows promise in solid tumors. This segment offers the best long-term growth prospects. Investors should monitor adoption rates and clinical trial progress for pipeline candidates. Oncology expansion could offset declines in legacy franchises.
Stock Performance and Investment Outlook
Gilead Sciences stock has demonstrated resilience despite sector headwinds. Current technical and fundamental positioning provides context for earnings expectations.
Recent Price Action and Technical Setup
GILD trades at $133.48, up 0.6% today and 29.8% over the past year. The stock sits between its 50-day average of $139.96 and 200-day average of $126.92, suggesting consolidation. Year-to-date performance of 8.75% trails the broader market. Volume of 5.96 million shares remains below the 6.39 million average, indicating modest trading interest ahead of earnings.
Growth Trajectory and Future Outlook
EPS growth of 17% year-over-year demonstrates strong earnings expansion. Net income growth of 16.7% outpaces revenue growth of 2.4%, reflecting operational leverage. This divergence suggests management successfully controls costs while growing the top line. Five-year revenue growth per share of 20.5% indicates the company navigates competitive pressures effectively.
Dividend and Shareholder Returns
Gilead maintains a dividend yield of 2.38%, providing income alongside capital appreciation potential. The payout ratio of 47% leaves room for dividend growth. The company returned capital through buybacks, reducing share count by 0.24% year-over-year. This balanced approach supports long-term shareholder value creation.
Final Thoughts
Gilead Sciences enters its May 7 earnings report with strong momentum and analyst support. The company’s consistent track record of beating EPS estimates, combined with solid revenue performance, suggests potential for another positive surprise. While revenue estimates show sequential decline, this reflects normal seasonal patterns rather than fundamental weakness. The B+ Meyka AI grade reflects balanced fundamentals, strong profitability metrics, and analyst consensus. Key focus areas include HIV franchise stability, hepatitis C segment trends, and oncology portfolio growth. With 32 buy ratings and only 3 holds, the market expects solid execution. Investors should monitor guidance for pi…
FAQs
What EPS and revenue do analysts expect from Gilead’s May 7 earnings?
Analysts expect $1.89 EPS and $6.91 billion revenue. EPS is slightly below the prior quarter’s $1.86 actual, while revenue reflects typical seasonal decline from the previous $7.925 billion.
Has Gilead beaten earnings estimates recently?
Yes. Gilead beat EPS estimates in two of the last three quarters: February 2026 ($1.86 vs. $1.81) and August 2025 ($2.01 vs. $1.96), suggesting potential for another beat.
What should investors watch during the earnings call?
Monitor HIV franchise trends, hepatitis C stabilization, and oncology growth. Focus on pipeline progress, margin expansion, capital allocation, and competitive pressures.
What does Meyka AI’s B+ grade mean for Gilead?
The B+ grade reflects solid fundamentals, strong profitability, and positive analyst consensus. It suggests balanced risk-reward for healthcare investors relative to sector performance.
Is Gilead’s dividend safe given earnings trends?
Yes. The 47% payout ratio provides substantial cushion. Free cash flow of $7.61 per share easily covers the $3.19 annual dividend with strong operating cash flow.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Earnings estimates are analyst projections and not guarantees of actual results. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask Meyka Analyst about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)